Dr. Andrius Baskys is a practicing psychiatrist, neuroscientist, inventor and educator. He has over 30 years of experience in mental health care and research focusing on memory disorders, their diagnosis and treatment. He completed his psychiatry residency at the University of Toronto, Canada, clinical fellowship at McMaster University, Hamilton and post-doctoral training at the University of California San Francisco. During his career, he has taught and conducted research as a faculty member at the University of Toronto, University of California Irvine, UCLA as well as, more recently, holding a visiting Professorship at the Fourth Military Medical University (FMMU) in Xi’an, China. Dr. Baskys published over 200 papers, presentations and reports and two textbooks on psychopharmacology. His most important scientific contributions are in the area of metabotropic glutamate receptor physiology and pharmacology. His research interests are pharmacogenomics, vascular dementia and development of AI-powered tools for bringing pharmacogenomic information to clinical practice.
Dr. Baskys serves on the Editorial Boards of Current Neuropharmacology and Clinical Handbook of Psychothropic Drugs. He is a member of the International Expert Panel for the Singapore Ministry of Health and is the Vice President of the World Association of Genomic Medicine headquartered in La Coruña, Spain.
SELECTED PUBLICATIONS
- 1.Baskys A. Clinical Handbook of Psychotropic drugs. A. Pharmacogenomic Information for Common Psychotropic Drugs. 22nd ed; Procyshyn, R.M.; Bezchlibnyk-Butler, K.Z.; Jeffries, J.J., Eds.; Hogrefe, 2017. [Google Scholar]
- 2.Cheung Y., Summerour R.B., Cui X., Baskys A. Testing for CYP polymorphisms is associated with a reduction in the frequency of changes in psychotropic prescriptions made by community psychiatrists. J. Genom. Med. Pharmacog. 2016;1:1–5. [Google Scholar]
- 3.Baskys A. Integration of genomic information in development of pharmacological vascular dementia prevention and treatment strategies. J. Alzheimers Dis. 2014;42(0) Suppl. 3:S267–S276. doi: 10.3233/JAD-140003. [PMID: 25024308]. [DOI] [PubMed] [Google Scholar]
- 4.Baskys A., Cheng J-X. Pharmacological prevention and treatment of vascular dementia: approaches and perspectives. Exp. Gerontol. 2012;47(11):887–891. doi: 10.1016/j.exger.2012.07.002. [http://dx.doi.org/10.1016/j.exger.2012.07.002]. [PMID: 22796225]. [DOI] [PubMed] [Google Scholar]
- 5.Koontz J., Baskys A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. Am. J. Alzheimers Dis. Other Demen. 2005;20(5):295–302. doi: 10.1177/153331750502000502. [http://dx.doi.org/10. 1177/153331750502000502]. [PMID: 16273995]. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Baskys A., Bayazitov I., Fang L., Blaabjerg M., Poulsen F.R., Zimmer J. Group I metabotropic glutamate receptors reduce excitotoxic injury and may facilitate neurogenesis. Neuropharmacology. 2005;49(Suppl. 1):146–156. doi: 10.1016/j.neuropharm.2005.04.029. [http://dx.doi.org/10. 1016/j.neuropharm.2005.04.029]. [PMID: 16023152]. [DOI] [PubMed] [Google Scholar]
- 7.Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J. Clin. Psychiatry. 2004;65(Suppl. 11):16–22. [PMID: 15264967]. [PubMed] [Google Scholar]
- 8.Blaabjerg M., Baskys A., Zimmer J., Vawter M.P. Changes in hippocampal gene expression after neuroprotective activation of group I metabotropic glutamate receptors. Brain Res. Mol. Brain Res. 2003;117(2):196–205. doi: 10.1016/s0169-328x(03)00321-8. [http://dx.doi.org/10.1016/S0169-328X(03)00321-8]. [PMID: 14559154]. [DOI] [PubMed] [Google Scholar]
- 9.Baskys A., Malenka R.C. Metabotropic glutamate receptor agonists depress synaptic transmission in area CA1 of rat hippocampus. J. Physiol. 1991;444:687–701. doi: 10.1113/jphysiol.1991.sp018901. [http://dx.doi.org/10.1113/jphysiol.1991.sp018901]. [PMID: 1668353]. [DOI] [PMC free article] [PubMed] [Google Scholar]